Minerva Neurosciences, Inc. financial data

Symbol
NERV on Nasdaq
Location
Burlington, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 05 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 689% % -25%
Debt-to-equity -206% % 18%
Return On Equity 46% % 357%
Return On Assets -44% % -548%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 6,993,406 shares 0%
Common Stock, Shares, Outstanding 6,993,406 shares 0%
Entity Public Float $12,900,000 USD -65%
Common Stock, Value, Issued $699 USD 0%
Weighted Average Number of Shares Outstanding, Basic 7,568,981 shares 0%
Weighted Average Number of Shares Outstanding, Diluted 7,568,981 shares 0%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $5,568,752 USD -62%
General and Administrative Expense $9,074,784 USD -8%
Operating Income (Loss) $14,643,536 USD 40%
Net Income (Loss) Attributable to Parent $14,027,562 USD -324%
Earnings Per Share, Basic -1 USD/shares -362%
Earnings Per Share, Diluted -1 USD/shares -362%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $12,286,646 USD -54%
Assets, Current $13,020,179 USD -53%
Property, Plant and Equipment, Net $1,360 USD -80%
Goodwill $14,869,399 USD 0%
Assets $28,092,052 USD -34%
Accounts Payable, Current $944,492 USD 71%
Liabilities, Current $2,672,322 USD -40%
Liabilities $62,672,322 USD -2.8%
Retained Earnings (Accumulated Deficit) $405,132,077 USD -3.6%
Stockholders' Equity Attributable to Parent $34,580,270 USD -60%
Liabilities and Equity $28,092,052 USD -34%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $4,071,960 USD 33%
Net Cash Provided by (Used in) Financing Activities $0 USD
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 125,000,000 shares 0%
Common Stock, Shares, Issued 6,993,406 shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,071,960 USD 33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $12,386,646 USD -53%
Deferred Tax Assets, Valuation Allowance $96,054,353 USD -0.84%
Deferred Tax Assets, Gross $96,054,353 USD -0.84%
Deferred Tax Assets, Operating Loss Carryforwards $42,922,972 USD 24%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD -100%
Share-based Payment Arrangement, Expense $1,117,994 USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%